Blockchain Registration Transaction Record

Race Oncology's Breakthrough in Cancer Cell Treatment

Race Oncology's CEO Dr. Daniel Tillett discusses promising preclinical findings indicating that combining bisantrene with decitabine enhances the destruction of cancer cells, potentially expanding decitabine's use beyond blood cancers to solid tumors. The study involved screening the combination across 143 cancer cell lines from over 20 human tissues, showing a significant increase in cancer cell death.

The promising preclinical findings of combining bisantrene with decitabine to enhance the destruction of cancer cells across various types could lead to new treatment avenues and potentially benefit individuals with solid tumors such as lung, prostate, pancreas, breast, and head and neck cancers. This breakthrough may have a significant impact on the future of cancer treatment and highlights the potential for a shift in the use of decitabine from blood cancers to solid tumors.